Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
In an attempt to create a single device that can image and treat tumors simultaneously, researchers at the University of Texas Southwestern Medical Center at Dallas have successfully melded magnetic iron nanoparticles, the anticancer drug doxorubicin, and a polymer tagged with a tumor-targeted molecule into a stable nanoparticle that accumulates inside human tumor cells.
African-American women with breast cancer were more likely to have larger, later-stage tumors that were more difficult to treat and also had lower survival rates than Hispanic and Caucasian women who received the same treatment in two independent series of clinical trials examined by researchers from The University of Texas M. D. Anderson Cancer Center.
Many of the most potent anticancer agents are poorly soluble in water, presenting a challenge for medicinal chemists who must develop methods of delivering these drugs in the watery environment of the human body.
Using temperature-sensitive, lipid- and polymer-based nanoparticles with a polymer coating, researchers in Korea have created an anticancer drug delivery vehicle that may provide a significant boost to the therapeutic efficacy of anticancer agents, particularly when used in conjunction with hyperthermia.
Investigators developing an inhalable nanoparticle for treating lung cancer have shown that a surface molecule found on malignant lung cells can serve as an effective target for improving drug delivery.
Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy.
It is well documented that some anti-cancer drugs can damage the heart, but a long-term follow-up of children and young adults who had doxorubicin treatment for bone tumours suggests that the damage gets progressively worse as the years go on.
A novel combination of lipids, a negatively charged polymer, and the anticancer drug doxorubicin has yielded a new nanoparticle that can kill breast cancer cells that are normally resistant to this drug.
Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.
Women who undergo surgery for breast cancer followed by radiation therapy often experience breast deformities that can only be corrected through reconstructive surgery.
When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the Journal of the American Medical Association.
Research studies, based at the University of Pennsylvania, demonstrate that biodegradable nano-particles containing two potent cancer-fighting drugs are effective in killing human breast tumors.
Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.
Treatment of human cancer is often impeded when cancer cells develop resistance to drugs that are designed to induce a type of programmed cell death called apoptosis.
Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast "plumbing" might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.
Complex chemotherapy cocktails offer about one extra month of life to patients with end-stage endometrial cancer but also can result in severe, possibly fatal, side effects, according to the first systematic review of studies addressing the topic.
Last year a group of Massachusetts General Hospital (MGH) researchers announced surprising findings that female mice - contrary to longstanding theories of mammalian reproductive physiology - retained the ability to make new egg cells or oocytes into adulthood.